Coexistence of aberrant hematopoietic and stromal elements in myelodysplastic syndromes
Introduction
Myelodysplastic syndromes are a heterogeneous group of disorders characterized by ineffective hematopoiesis resulting in cytopenias of one or more lineages and a variable risk of progression to acute myeloid leukemia [1]. The pathogenesis of MDS is not well defined, but the presence of dysplastic myeloid elements in the bone marrow and specific cytogenetic abnormalities or mutations are found in 60–70% of cases [1]. Chromosomal aberrations in MDS can vary from simple to complex, the most frequent being del (5q), monosomy 7, del (7q), trisomy 8, and del (20q). Other aberrations such as del (17p), del (12p), del (11q23) and the loss of chromosome Y also occur albeit at lower frequencies [2], [3]. These changes were attributed to an abnormal hematopoietic stem cell (HSC) since > 95% of cytogenetic abnormalities were observed in the most primitive HSCs and when transplanted in a xenotransplantation model were able to initiate clonal MDS [4], [5], [6], [7], [8], [9]. Given that the bone marrow niche hosts and maintains hematopoietic stem cells and that patients with MDS have a compromised hematopoiesis, it is likely that abnormalities of the niche could contribute to disease pathogenesis [10]. This concept is supported by the presence of cytogenetic abnormalities, impaired capacity to support hematopoiesis and aberrant generation of key niche factors such as Angptl4, Vegfa and Lif in cultured mesenchymal stromal cells (MSCs) [11], [12], [13], [14]. Further proof of the role of MSC in pathogenesis of MDS came from a recent study wherein a cohort of low-risk MDS patients, co-injection of CD34 + cells with the corresponding in vitro cultured MSCs demonstrated dramatic improvement in engraftment with a myeloid bias, suggesting that bone marrow stromal cells provide key auxiliary signals for MDS pathogenesis [11]. Upregulation of proangiogenic cytokine-like Vegfa, an increase in endothelial colony forming cells (ECFCs), and aberrant angiogenesis in MDS bone marrow suggest that other stromal elements could also contribute to disease pathogenesis [15], [16], [17]. Taken together, these profound alterations at the molecular and functional level suggest that abnormalities may exist in multiple components of the bone marrow or the HSC niche. So far these studies have mostly evaluated only one component either in vitro expanded cells or bone marrow sections. It is likely this isolated approach could have a skewed or masked response from other stromal elements in vivo.
To study the role of different stromal elements in these bone marrow samples, we employed mesenchymal subset selection strategy based on the CD146 and CD271 expression. Since in situ localization studies in human bone marrow showed CD146 is expressed on MSCs located in the perivascular region, but it is absent on MSCs resident in the bone-lining location, while cells coexpressing CD271 and CD146 are present in the sub-endothelial layer of sinusoids. CD271 + CD146 − MSCs reside in the trabecular bone-lining endosteal niche [18].
This study was undertaken to simultaneously evaluate abnormalities in the HSC and myeloid progenitors along with the other components of the stroma in a cohort of MDS patients with refractory cytopenia with multilineage dysplasia (RCMD).
Section snippets
Patients and bone marrow samples
The study included 17 patients (14 with RCMD, 3 with RA/RARS) and 20 age-matched controls with ‘normal’ marrow obtained for other diagnostic purposes (see Table 1, Table 2 for details). We selected the controls with morphologically normal marrow in diseases, where no known abnormalities exist in the hematopoietic stem cell or the stroma (see Table 1 for details). The study was approved by the Institutional Review board of the Christian Medical College, Vellore, India. Mononuclear cells were
Loss of LT-HSCs in RCMD patients
By employing specific-defined markers in the method section above for LT-HSCs and HSPCs, we compared frequencies of highly fractionated LT-HSCs, HSPCs and committed progenitors among patients with RCMD and refractory anemia/refractory anemia with ring sideroblasts (RA/RARS) with age-matched controls (Table 1, Fig. 1a). Phenotypic enumeration of LT-HSCs and HSPC1 in RA/RARS did not show significant change (p = NS) in their frequencies when compared to controls (Supporting information, Fig. S1A).
Discussion
Our data on comprehensive evaluation of HSC and stromal components in the bone marrow of patients with MDS RCMD demonstrates that aberrations are present in several of these elements in the same patient. As shown in our data and consistent with earlier reports [7], [8], RCMD patients had a 11-fold loss of LT-HSCs and 7-fold loss of the corresponding HSPC1 compared to controls. The concurrent analysis also revealed no significant alteration in frequency of HSPC2 and HSPC3 populations between
Acknowledgments
We would like to thankfully acknowledge Maulana Azad National Fellowship, University Grants Commission (UGC), Government of India to Salar Abbas. The authors also acknowledge technical support from core facilities of Centre for Stem Cell Research (CSCR), A unit of Institute for Stem Cell Biology and Regenerative Medicine (inStem), Government of India. This work was supported in part from Fluid Research Grant from Christian Medical College, Vellore, Tamil Nadu, India (CMC Res/2/2011 (IRB Min.
Conflict of interest
None.
References (38)
- et al.
The genetic basis of myelodysplastic syndromes
Hematol. Oncol. Clin. North Am.
(2010) - et al.
Involvement and functional impairment of the CD34 + CD38- Thy-1 + hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8
Blood
(2002) - et al.
The molecular signature of MDS stem cells supports a stem-cell origin of 5q − myelodysplastic syndromes
Blood
(2007) - et al.
Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level
Blood
(2000) - et al.
Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations
Blood
(2012) - et al.
Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo
Cancer Cell
(2014) - et al.
Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit
Cell Stem Cell
(2014) - et al.
Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts
Blood
(2011) - et al.
Functional characteristics of mesenchymal stem cells derived from bone marrow of patients with myelodysplastic syndromes
Cancer Lett.
(2012) - et al.
Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes
Blood
(2001)
Endothelial progenitor cell dysfunction in myelodysplastic syndromes: possible contribution of a defective vascular niche to myelodysplasia
Neoplasia
CD146 expression on primary nonhematopoietic bone marrow stem cells is correlated with in situ localization
Blood
Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment
Cell
Isolation of bone marrow mesenchymal stem cells by anti-nerve growth factor receptor antibodies
Exp. Hematol.
Distinctive contact between CD34 + hematopoietic progenitors and CXCL12 + CD271 + mesenchymal stromal cells in benign and myelodysplastic bone marrow
Lab. Investig.
A human stromal-based serum-free culture system supports the ex vivo expansion/maintenance of bone marrow and cord blood hematopoietic stem/progenitor cells
Exp. Hematol.
Hypoxic induction of vascular endothelial growth factor regulates murine hematopoietic stem cell function in the low-oxygenic niche
Blood
Angiogenesis in relation to clinical stage, apoptosis and prognostic score in myelodysplastic syndromes
Leuk. Res.
Myelodysplastic syndromes
N. Engl. J. Med.
Cited by (6)
Myeloid‐derived suppressor cells and mesenchymal stem/stromal cells in myeloid malignancies
2021, Journal of Clinical MedicineHuman primary bone marrow stromal cells-basic biology and isolation strategies
2020, Encyclopedia of Bone BiologyHeterogeneity of Mesenchymal Stromal Cells in Myelodysplastic Syndrome-with Multilineage Dysplasia (MDS-MLD)
2019, Indian Journal of Hematology and Blood TransfusionEffects of bone marrow mesenchymal cells from immune thrombocytopenia patients on the biological behaviors of megakaryocytes
2018, Journal of Shanghai Jiaotong University (Medical Science)